SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 64.92-0.3%May 20 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: donpat9/11/2006 6:07:06 PM
  Read Replies (1) of 347
 
GenoMed: Cure for Sickle Cell Pain

Monday September 11, 9:30 am ET

ST. LOUIS, Sept. 11 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED - News), the Next Generation Disease Management company whose business is public health(TM), announced today that it has submitted a case report of a sickle cell patient whose pain disappeared with GenoMed's treatment approach, only to recur when it was stopped.

The patient is a middle-aged African American woman who for years required multiple pain pills every day to tolerate the pain of her sickle cell disease. Since beginning GenoMed's trial on Dec. 22, 2005, she experienced no pain until her trial medication ran out on February 6, 2006. Said her physician, who is lead author on the case report, "Prior to this experiment, for over two years, there has not been more than a day, at least during the winter months, when she has not required some Vicodin."

Her pain ceased within a few days of resuming GenoMed's treatment in February. In June, her physician intentionally stopped GenoMed's treatment. Off GenoMed's treatment, the patient's pain recurred within a week. When she again resumed GenoMed's treatment, her pain again stopped within a few days. She has been pain-free on GenoMed's treatment for three months now, since June.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Although only a single patient, she satisfied Koch's postulates, which constitute a rigorous clinical test. As long as the patient was using our treatment, her pain was gone. On two occasions, one accidental and one deliberate, our treatment was stopped. On both occasions her pain recurred promptly, only to disappear quickly after treatment was resumed. It doesn't get much more convincing than this."

Added Dr. Moskowitz, "Ever since Max Perutz showed the molecular defect in sickle cell hemoglobin in 1946, for which he won the Nobel Prize, sickle cell disease has been a sober reminder that knowing the molecular cause of a disease is still a far cry from curing it."

Dr. Moskowitz ended by saying, "We're eager to acquire more sickle cell patients to see if what has cured this patient's pain will work for every patient. It's fitting that our potential cure comes during America's Sickle Cell Awareness and Pain Awareness Month."

About GenoMed

GenoMed owns patents pending for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including sickle cell disease. To enroll in GenoMed's sickle cell disease trial, please contact Dr. Moskowitz at dwmoskowitz@genomed.com .

Source: GenoMed
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext